PROGNOSTIC VALUE OF ADP-INDUCED PLATELET AGGREGATION IN PEPTIC ULCER–RELATED GASTROINTESTINAL BLEEDING AMONG PATIENTS RECEIVING ANTIPLATELET THERAPY
Main Article Content
Abstract
Background: Gastrointestinal bleeding (GIB) is a severe and common complication in patients receiving antiplatelet therapy. Excessive platelet inhibition, reflected by adenosine diphosphate (ADP)-induced platelet aggregation testing, may significantly increase bleeding risk. This study aimed to evaluate the relationship between the degree of platelet inhibition (ADP%) and the severity of peptic ulcer–related GIB in patients taking antiplatelet agents.
Methods: A prospective observational study was conducted on 32 patients with peptic ulcer–related GIB who were taking aspirin and/or clopidogrel. ADP testing was performed within 24 hours of hospital admission using the LTA system. Clinical parameters, including hemoglobin (Hb), Rockall score, Glasgow–Blatchford score (GBS), and transfused blood volume, were analyzed in relation to ADP values.
Results: The mean ADP value was 38.5 ± 15.2%. Patients with ADP <40% had lower Hb (74.1 ± 9.9 vs. 89.4 ± 14.6 g/L; p = 0.021), higher Rockall and GBS scores (p = 0.035 and 0.046, respectively), and nearly three times higher transfusion volume (1108 ± 579 vs. 381 ± 338 mL; p < 0.001). A moderate negative correlation was found between ADP and transfusion volume (r = –0.52; p = 0.0021).
Conclusion: Strong platelet inhibition (low ADP%) is closely associated with greater severity of gastrointestinal bleeding in patients receiving antiplatelet therapy. ADP testing may serve as a valuable tool for early risk stratification and individualized management in high-risk patients.
Article Details
Keywords
Gastrointestinal Hemorrhage, Peptic Ulcer, Platelet Aggregation Inhibitors, Adenosine Diphosphate, Platelet Function Tests, Risk Assessment
References
[2] Lanas A, Carrera-Lasfuentes P, Arguedas Y, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2015;13(5):906-912.e2. doi:10.1016/j.cgh.2014.11.007.
[3] Silvain J, Cayla G, Hulot JS, et al. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. Eur Heart J. 2012;33(10):1241-1249. doi:10.1093/eurheartj/ehr407.
[4] Kringen MK, Narum S, Lygren I, et al. Reduced platelet function and role of drugs in acute gastrointestinal bleeding. Basic Clin Pharmacol Toxicol. 2011;108(3):194-201. doi:10.1111/j.1742-7843.2010.00643.x.
[5] Barinov E, Sulaieva O, Lyakch Y, et al. Platelet aggregation measurement for assessment of hemostasis failure mechanisms in patients with gastroduodenal ulcer bleeding. Clin Exp Gastroenterol. 2013;6:139-148. doi:10.2147/CEG.S45685.
[6] Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121(4):512-518. doi:10.1161/CIRCULATIONAHA.109.885194.
[7] Cattaneo M. P2Y12 receptors: structure and function. J Thromb Haemost. 2015;13 Suppl 1:S10-S16. doi:10.1111/jth.12952.
[8] Abraham NS, Barkun AN, Sauer BG, et al. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. Am J Gastroenterol. 2022;117(4):542-558. doi:10.14309/ajg.0000000000001627.